
    
      The study consists of three parts. Part 1 is a prospective non-randomized feasibility study
      in patients with breast cancer after primary surgery during chemotherapy or endocrine therapy
      comparing blood count, lymphocytes, quality of life and local and general side effects
      between the groups Part 2 is a prospective randomized feasibility study with a waiting list
      for three months comparing changes in quality of life, depression, diurnal cortisol profile
      and expression of zeta-chains in T- and NK-cells after three months of treatment or waiting
      in patients of two different strata (early breast cancer UICC I/II and metastatic breast
      cancer) Part 3 consists of two follow-up periods of 12 months respective. Patients may choose
      to continue, quit or restart mistletoe treatment upon their own decision, endpoints from part
      2 are evaluated every 6 months.
    
  